Essential Hypertension Clinical Trial
— SORTOfficial title:
A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.
Verified date | June 2013 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | India: Drugs Controller General of India |
Study type | Observational |
The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.
Status | Completed |
Enrollment | 1514 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Newly diagnosed essential hypertension patients will be eligible for the study. - Average of two or more systolic BP readings = 140mmHg or diastolic BP readings = 90mmHg Exclusion Criteria: - History of coronary artery disease - History of diabetes |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
India | Research Site | Agartala | |
India | Research Site | Agra | |
India | Research Site | Ahmedabad | |
India | Research Site | Aligarh | |
India | Research Site | Ambattur | |
India | Research Site | Amritsar | |
India | Research Site | Aurangabad | |
India | Research Site | Bangalore | |
India | Research Site | Barelly | |
India | Research Site | Baroda | |
India | Research Site | Batanagar | |
India | Research Site | Beed | |
India | Research Site | Belgaum | |
India | Research Site | Bhagal | |
India | Research Site | Bhongi | |
India | Research Site | Bhopal | |
India | Research Site | Bhuj | |
India | Research Site | Burdwan | |
India | Research Site | Chandigarh | |
India | Research Site | Chennai | |
India | Research Site | Chomv | |
India | Research Site | Coimbatore | |
India | Research Site | Davangere | |
India | Research Site | Delhi | |
India | Research Site | Dhule | |
India | Research Site | Dombivli | |
India | Research Site | Ellisbridge | |
India | Research Site | Fariadad | |
India | Research Site | Faridabad | |
India | Research Site | Gandhinagar | |
India | Research Site | Ghatkopar East | |
India | Research Site | Ghaziabad | |
India | Research Site | Gulbarga | |
India | Research Site | Guntur | |
India | Research Site | Gurgaon | |
India | Research Site | Gwalior | |
India | Research Site | Hanamkonda | |
India | Research Site | Hooghly | |
India | Research Site | Hubli | |
India | Research Site | Hyd | |
India | Research Site | Hyderabad | |
India | Research Site | Indore | |
India | Research Site | Jabalpur | |
India | Research Site | Jaipur | |
India | Research Site | Jalandhar | |
India | Research Site | Jalgoon | |
India | Research Site | Kakinada | |
India | Research Site | Kanpur | |
India | Research Site | Karad | |
India | Research Site | Karimnagar | |
India | Research Site | Kolhapur | |
India | Research Site | Kolkata | |
India | Research Site | Kolkata- | |
India | Research Site | Kulhapu | |
India | Research Site | Kumta | |
India | Research Site | Lucknow | |
India | Research Site | Ludhiana | |
India | Research Site | Madhyamgram | |
India | Research Site | Madurai | |
India | Research Site | Miroj | |
India | Research Site | Mohali | |
India | Research Site | Mozda | |
India | Research Site | Mrit Home | |
India | Research Site | Mulund | |
India | Research Site | Mumbai | |
India | Research Site | Murshidabad | |
India | Research Site | Nadiad | |
India | Research Site | Nagpur | |
India | Research Site | Nasik | |
India | Research Site | Naugloi | |
India | Research Site | Navi Mumbai | |
India | Research Site | Nesul | |
India | Research Site | New Delhi | |
India | Research Site | New Panvel | |
India | Research Site | Newdelhi | |
India | Research Site | Nipani | |
India | Research Site | Op Inchapur | |
India | Research Site | Palanpur | |
India | Research Site | Panvel. | |
India | Research Site | Parganas (Wb) | |
India | Research Site | Pune | |
India | Research Site | Raipur | |
India | Research Site | Rajkot | |
India | Research Site | Sahibabad,Gzb | |
India | Research Site | Secenderabad | |
India | Research Site | Shakar Pur | |
India | Research Site | Shimoga | |
India | Research Site | Sonarpur | |
India | Research Site | Sowcarpet | |
India | Research Site | Surat | |
India | Research Site | Thane | |
India | Research Site | Tirupati | |
India | Research Site | Ulhasnagar | |
India | Research Site | Vadodara | |
India | Research Site | Vijayawada | |
India | Research Site | Virar | |
India | Research Site | Visakhapatnam | |
India | Research Site | Vizag | |
India | Research Site | Warangal |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of SO in newly diagnosed hypertensive patients | Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion. | No | |
Secondary | Association of SO and heart rate. | Visits 1-3 | No | |
Secondary | Subjective symptoms noticed by the doctor. | 1st visit | No | |
Secondary | To record the drugs used in the treatment of patients diagnosed with hypertension. | Visits 1-3 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
Completed |
NCT06395194 -
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT06418074 -
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity
|
N/A | |
Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|